Efficacy and safety of Biogen’s anti-TNF biosimilars presented at EULAR
Data demonstrating long-term comparable efficacy, safety and immunogenicity of biosimilars Benepali (etanercept) and Flixabi (infliximab) have been presented at the Annual European Congress of Rheumatology (EULAR 2016).
Click on this link for more information.
